Heavy Chain Disease – Alpha (IPSID / Mediterranean Lymphoma)
Alpha heavy chain disease (alpha-HCD) is the most common form of heavy chain disease, presenting as a lymphoproliferative disorder of the small intestine (IPSID) that is closely associated with Campylobacter jejuni infection and is treatable with antibiotics at early stages.
- Most Common Heavy Chain Disease
- Antibiotic-Responsive in Early Stages
- GI Specialist & Hematology Evaluation Essential
- Access to Expert Centers for Advanced Disease
- Affected Population
- Young adults in Middle East, North Africa, South Asia
- Primary Site
- Small intestine (proximal jejunum and duodenum)
- Association
- Campylobacter jejuni infection (early-stage); MALT lymphoma biology
- Early-Stage Treatment
- Antibiotics (tetracycline, metronidazole) can induce remission
- Advanced Therapies
- CHOP-based chemotherapy, rituximab (CD20 if expressed)
Condition Overview
Alpha heavy chain disease (alpha-HCD), also known as immunoproliferative small intestinal disease (IPSID) or Mediterranean lymphoma, is the most common of the three heavy chain diseases. It is characterized by the production of truncated alpha immunoglobulin heavy chains — devoid of light chains — by malignant plasma cells or lymphoplasmacytic cells infiltrating the small intestinal mucosa.
Alpha-HCD predominantly affects young adults in geographic regions including North Africa, the Middle East, South Asia, and parts of Latin America, where it is associated with environmental factors and chronic infection — particularly Campylobacter jejuni. At the histologic level, it shares biology with mucosa-associated lymphoid tissue (MALT) lymphoma of the small bowel, and early-stage disease may respond completely to antibiotic therapy targeting the underlying infection.
Advanced-stage alpha-HCD transforms into an aggressive large B-cell lymphoma-like disorder requiring systemic chemotherapy. Accurate staging through endoscopic biopsy, immunophenotyping, and imaging is critical to determining whether antibiotics alone can be attempted or whether chemotherapy is needed.
Types and Subtypes
Alpha-HCD is classified by histologic stage of disease progression. Three stages describe the spectrum from reactive lymphoplasmacytic infiltration through to frank aggressive lymphoma, and this staging directly determines treatment approach.
Symptoms and Signs
Alpha-HCD presents primarily with gastrointestinal symptoms related to small intestinal infiltration and malabsorption. The disease course is often prolonged and insidious, with symptoms evolving over months to years before diagnosis.
Causes and Risk Factors
Alpha-HCD is strongly associated with chronic intestinal infection and a background of poor sanitary conditions in endemic geographic regions. Like gastric MALT lymphoma (linked to H. pylori), IPSID/alpha-HCD in its early stages is driven by antigen-stimulated B-cell proliferation responding to microbial triggers — particularly Campylobacter jejuni — that can be eliminated with antibiotic treatment.
Diagnosis and Investigations
Diagnosis of alpha-HCD requires histopathologic confirmation from small intestinal biopsies combined with immunophenotyping and serum protein electrophoresis demonstrating the truncated alpha heavy chain. Endoscopy is the cornerstone of diagnosis, and correct staging requires assessment of the depth and extent of bowel infiltration.
Staging and Risk Stratification
Alpha-HCD is staged histologically using the Galian staging system, which defines the extent of intestinal wall invasion and the degree of lymphoid atypia. This staging directly guides treatment decisions — whether antibiotics alone, combined antibiotics and chemotherapy, or chemotherapy-first approaches are appropriate.
Standard Treatment Options
Treatment strategy in alpha-HCD is determined by disease stage. Early-stage (Stage A) disease is treated with antibiotics; advanced transformation (Stage C) requires anthracycline-based chemotherapy. The ability to diagnose disease at an early, antibiotic-responsive stage is a key goal of management in endemic populations.
Advanced & Emerging Therapies
Most advances in the treatment of alpha-HCD in its transformed (Stage C) form follow the trajectory of diffuse large B-cell lymphoma. For refractory or relapsed disease, options being evaluated include novel immunotherapy and targeted approaches.
Immunotherapy
Rituximab (Anti-CD20) + CHOP (R-CHOP)
When CD20 is expressed on the lymphoma cells in Stage C or CD20-positive Stage B alpha-HCD, rituximab combined with CHOP chemotherapy is a standard and effective approach, consistent with DLBCL treatment principles.
Targeted Therapy
BTK Inhibitors (Ibrutinib, Zanubrutinib)
BTK inhibitors are active in MALT lymphoma and related B-cell lymphoproliferative disorders. Their role in alpha-HCD, particularly for antibiotic-refractory Stage A/B disease without full transformation, is under investigation based on shared MALT biology.
Immunotherapy
PD-1/PD-L1 Checkpoint Inhibitors
In patients with relapsed or refractory Stage C transformation to aggressive lymphoma failing standard regimens, checkpoint inhibitors are being explored as part of salvage strategies. Evidence specific to alpha-HCD is limited; case reports and small series exist.
Cellular Therapy
CAR-T Cell Therapy (for Stage C DLBCL Transformation)
If Stage C disease transforms to CD19-positive diffuse large B-cell lymphoma and fails two or more lines of therapy, CD19-directed CAR-T cell therapy (tisagenlecleucel, axicabtagene ciloleucel) may be considered following established DLBCL relapse guidelines. Access available at CAR-T certified centers in India, China, and major international centers.
Precision Medicine
NGS-Guided Targeted Therapy
Next-generation sequencing of transformed alpha-HCD may identify actionable mutations (PI3K pathway, MYD88, CD79B) that could guide targeted therapy options in relapsed/refractory settings.
Biomarkers & Precision Medicine
Biomarker assessment in alpha-HCD is focused on confirming the diagnosis of the truncated alpha heavy chain, characterizing the B-cell phenotype for CD20 and other therapeutic targets, and identifying transformation to aggressive lymphoma.
When to Seek a Second Opinion
Alpha-HCD is exceptionally rare, and most general hematologists or gastroenterologists will have limited experience with this diagnosis. A second opinion at a center with expertise in rare lymphoproliferative disorders and GI lymphoma is strongly recommended in the following situations.
Clinical Trials & Research
Prognosis & Outcomes
Prognosis in alpha-HCD is strongly stage-dependent. Stage A disease, if diagnosed early and treated with appropriate antibiotics, carries an excellent prognosis with the potential for complete and durable remission. Advanced disease with Stage C transformation carries a more guarded prognosis consistent with aggressive lymphoma, though responses to chemotherapy are achievable.
Supportive Care and Living With Alpha-HCD
Malabsorption is a defining feature of alpha-HCD, making nutritional support a cornerstone of care throughout diagnosis and treatment. Addressing deficiencies, managing treatment toxicity, and providing psychosocial support are all essential components of a comprehensive care plan.
How CancerFax Helps You Explore Treatment Options
CancerFax connects patients with alpha heavy chain disease (IPSID) to expert hematologists and GI lymphoma specialists for medical report review, accurate staging, and treatment coordination — including access to centers with experience in antibiotic-based protocols, CHOP/R-CHOP chemotherapy, and clinical trials for rare lymphoproliferative disorders.
Get a free case reviewFrequently Asked Questions
Alpha heavy chain disease (alpha-HCD), also known as immunoproliferative small intestinal disease (IPSID) or Mediterranean lymphoma, is a rare B-cell lymphoproliferative disorder of the small intestine. It is characterized by the abnormal production of truncated alpha immunoglobulin heavy chains — without accompanying light chains — by malignant or pre-malignant lymphoplasmacytic cells infiltrating the small bowel wall. It is the most common of the three types of heavy chain disease and is strongly associated with Campylobacter jejuni infection in endemic regions.
The most common early symptoms are chronic diarrhea (often fatty/oily stools reflecting malabsorption), progressive weight loss, abdominal pain, and fatigue. Because the small intestine is infiltrated and its absorptive surface disrupted, patients may develop signs of malabsorption including low blood protein (hypoalbuminemia), anemia, and deficiencies of fat-soluble vitamins. These symptoms are nonspecific and overlap with many GI conditions, which often leads to delayed diagnosis.
Diagnosis requires endoscopy with small bowel biopsies showing characteristic lymphoplasmacytic infiltration, combined with serum immunofixation electrophoresis demonstrating truncated alpha heavy chains without light chains. Immunohistochemistry on biopsy tissue confirms B-cell lineage and plasma cell differentiation. CT scan and additional imaging assess the extent of intestinal and nodal involvement. Testing for Campylobacter jejuni infection is important as it informs antibiotic treatment planning.
Yes — in Stage A (early) disease, antibiotic therapy targeting Campylobacter jejuni (typically tetracycline or doxycycline with or without metronidazole) can induce complete histologic and serologic remission. This parallels the antibiotic treatment of early-stage gastric MALT lymphoma due to H. pylori. Antibiotic courses are typically 6–12 months long, with endoscopic reassessment at 3–6 months to confirm response. More advanced disease (Stage B and Stage C) requires the addition of or replacement with chemotherapy.
Stage B and Stage C alpha-HCD is treated with anthracycline-based chemotherapy, typically CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). If the lymphoma cells express CD20, rituximab is added to form R-CHOP, following the same approach used in diffuse large B-cell lymphoma. The number of treatment cycles and need for additional therapy depends on disease stage and treatment response.
Stage C alpha-HCD refers to histologic transformation from a low-grade lymphoplasmacytic infiltrate to an aggressive lymphoma — typically a diffuse large B-cell lymphoma (DLBCL) or immunoblastic lymphoma. At this stage, antibiotic therapy alone is no longer effective, and systemic chemotherapy (CHOP or R-CHOP) is required. Stage C is the most advanced and most challenging form of alpha-HCD, and prognosis is comparable to other aggressive B-cell lymphomas at a similar stage of disease.
Alpha-HCD is endemic in regions with historically poor sanitation and high rates of childhood intestinal infections — including North Africa, the Middle East, South Asia, and parts of South America. This geographic clustering is explained by the disease's association with Campylobacter jejuni infection and chronic antigen stimulation of gut lymphoid tissue. Improved sanitation in some regions has been associated with a decline in incidence over time.
Because alpha-HCD infiltrates and damages the absorptive mucosa of the small intestine, it causes protein-losing enteropathy and malabsorption of fats, fat-soluble vitamins (A, D, E, K), iron, vitamin B12, folate, calcium, and other micronutrients. This leads to hypoalbuminemia (low blood protein) causing edema, nutritional anemia, osteoporosis risk, coagulopathy, and peripheral neuropathy. Addressing these deficiencies through nutritional support — both during disease treatment and in recovery — is a central aspect of care.
Yes. CancerFax can assist patients with alpha heavy chain disease (IPSID) in accessing specialized hematology-oncology evaluation, expert second opinions on staging and treatment planning, and coordination with centers experienced in managing rare GI lymphoproliferative disorders. CancerFax can facilitate medical report review, connect patients to specialists familiar with antibiotic-based protocols and CHOP/R-CHOP chemotherapy, and help identify clinical trial access for refractory or relapsed disease in India, internationally, and at leading lymphoma programs worldwide.
Get Specialist Guidance on Alpha Heavy Chain Disease
Alpha-HCD is rare and complex — accurate staging and expert treatment decisions are critical. CancerFax connects you with experienced hematologists and GI oncology specialists for medical report review, second opinions, and access to advanced treatment options.